Wockhardt Ltd has signed its first in-licensing agreement in the anti-wrinkle segment of dermatology products with Italy''s Syrio Pharma S P A to market the Milan-based firms B-Lift range of skincare products.

Last week, the company had announced having signed an in-licensing agreement with the US-based Advanced Biotechnologies Inc to market a patent-protected Kelcote silicone gel used in the treatment of scars from accidents, burns, surgery and acne as well as skin disorders such as dermatitis and varicella. (See: Wockhardt to introduce treatment for dermatological scars)

The B-Lift range is based on a Botox like peptide and used for anti-ageing. However, unlike Botox, B-Lift said to be available as a gel and can be used on all patients. Wockhardt says the gel-based preparation is known to have a better safety profile than Botox.

Wockhardt will market the range, which would also include a topical gel for men.

In a regulatory filing, Wockhardt chairman Habil Khorakiwala is stated as saying, "Wockhardt has always strived to introduce newer and better products for the benefit of
Indian patients. We will soon introduce the B-Lift range of products to cater to patients seeking advanced skin renewal treatment in India."

The company plans to introduce the product range in the third quarter of 2007. IT was first launched in 2003 in Italy. The statement says that multi-country clinical data has proven its efficacy and safety.

The value of the anti-ageing segment in India is estimated at Rs200 crore, which Wockhardt expects would grow exponentially in the next two years with increasing lifestyle changes.

Wockhardt is in the process of assembling a specialiased field force to promote its skincare range among dermatologists.